Ozempic in a Tablet: What the Rebrand of Oral Semaglutide Actually Changes
Novo Nordisk folded Rybelsus into the Ozempic name in May and put a self-pay price on it. Getting a peptide to survive the stomach is a real achievement, but the tablet is not simply the injection in another form.
Tuesday, August 11, 2026/3 min read
In May 2026, Novo Nordisk rebranded Rybelsus, its oral semaglutide, as Ozempic tablets. Commercially this is a straightforward move: consolidate behind the name everyone already knows. Clinically it is a useful moment to explain something most coverage skips, which is why a pill version of this drug was difficult in the first place.
Why peptides are usually injected
Semaglutide is a peptide, a short chain of amino acids. Your digestive system is extremely good at breaking those down, because that is what it is for. Swallow a peptide and the stomach treats it as protein.
Oral semaglutide gets around this with an absorption enhancer, SNAC, which raises local pH around the tablet and helps the molecule cross the stomach lining before it is destroyed. It works, but only just, and the constraints show up in the dosing instructions.
Bioavailability is low and variable, which is why the tablet dose is far larger in milligrams than the injection and why the instructions are unusually strict:
- Take it on an empty stomach, first thing in the morning.
- With no more than about half a glass of plain water.
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines.
Those are not manufacturer fussiness. Eat too soon and absorption drops enough to matter. This is the trade-off of the tablet: convenience of route, inconvenience of routine.
Tablet or injection
The honest summary is that a weekly injection is simpler for most people than a daily tablet with a fasting window attached, and the injection has generally shown somewhat stronger weight effects at comparable positioning.
The tablet nevertheless matters for three groups.
- People with genuine needle aversion. Not a trivial category, and a real barrier to starting treatment.
- People who cannot manage cold chain storage. Tablets travel and store far more easily, which matters in hot climates and for anyone who travels frequently.
- People testing tolerance. A daily oral dose can be stopped immediately if side effects are severe, where a weekly injection has already been administered.
The pricing signal
The more consequential part of the announcement was the price. Novo's self-pay programme puts the injection at around 199 dollars a month and the pill at around 149, against list prices above 1,000 dollars a month for the branded injection.
That is a large gap, and it reflects a structural shift. The GLP-1 market has moved from a shortage economy, where the constraint was supply, to a competitive one, where the constraint is what patients and payers will actually pay. Direct self-pay channels are how manufacturers are responding.
It also removes some of the oxygen from the compounded market. Much of the demand for compounded semaglutide was driven by price and availability rather than preference, and it produced a serious counterfeit problem. A cheaper authorised route is the most effective response to that available.
What has not changed
The tablet is the same molecule with the same mechanism, the same side effect profile, and the same contraindications as the injection. Nausea, vomiting, diarrhoea and constipation remain the common complaints, and the exclusions listed in our guide to who should not take these drugs apply identically.
Two other constants are worth restating.
First, indications matter. Oral semaglutide's approval position is centred on type 2 diabetes, and prescribing for weight alone is a separate regulatory question in each market. Do not assume the tablet is licensed where you are for the reason you want it.
Second, the weight returns when you stop. This is the most consistent finding in the field, covered in the evidence on stopping, and it is unaffected by whether the drug arrived through a needle or a tablet.
The direction of travel
Oral delivery of peptides was considered close to impossible for decades. That it now exists at commercial scale is a genuine pharmaceutical achievement, and it points at where the field is going: oral formulations of the newer molecules, including the dual and triple agonists that currently require injection.
If a triple agonist of the kind described in the retatrutide results eventually arrives in tablet form, at a self-pay price, the access conversation changes completely. That is some way off. The tablet is the first step towards it.
Published in The Outspoken Digest
Editorial desk
Outspoken Digest Health DeskMedicine, public health and the research behind the headlines, read carefully.
Newsletter
The Digest, in your inbox
One edition, sent when it is ready. No noise, and your address is never passed on.
Read Next
More Health →
